Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry
Marie-Kristin Tilch,
Carlo Visco,
Sandra Kinda,
Olivier Hermine,
Milena Kohn,
Caroline Besson,
Sylvain Lamure,
Rémy Duléry,
Simone Ragaini,
Toby A. Eyre,
Tom Van Meerten,
Anke Ohler,
Steffen Eckerle,
Martin Dreyling,
Georg Hess,
Eva Giné,
Maria Gomes da Silva
Affiliations
Marie-Kristin Tilch
1 Department of Hematology, Oncology and Pneumology & University Cancer Center, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Carlo Visco
2 Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
Sandra Kinda
3 University Hospital Center Zagreb, Department of Internal Medicine, Division of Hematology, Zagreb, Croatia
Olivier Hermine
4 Department of Hematology, Hôpital Necker, Assistance Publique—Hôpitaux de Paris, France
Milena Kohn
5 Service d’Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Montigny le Bretonneux, France
Caroline Besson
5 Service d’Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Montigny le Bretonneux, France
Sylvain Lamure
6 Departement d’Hématologie Clinique, CHU de Montpellier, UMR-CNRS 5535, Université de Montpellier, France
Rémy Duléry
7 Sorbonne Université, INSERM UMRs938, Service d’Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France
Simone Ragaini
8 Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino/“Città della Salute e della Scienza di Torino” University Hospital, Turin, Italy
Toby A. Eyre
9 Department of Clinical Hematology, Oxford Cancer and Hematology Centre, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom
Tom Van Meerten
10 Department of Hematology, University of Groningen, University Medical Center Groningen, Netherlands
Anke Ohler
1 Department of Hematology, Oncology and Pneumology & University Cancer Center, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Steffen Eckerle
1 Department of Hematology, Oncology and Pneumology & University Cancer Center, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Martin Dreyling
11 Department of Medicine III, LMU Hospital, Munich, Germany
Georg Hess
1 Department of Hematology, Oncology and Pneumology & University Cancer Center, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Eva Giné
12 Department of Hematology, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain
Maria Gomes da Silva
13 Department of Hematology, Instituto Português de Oncologia de Lisboa, Portugal
Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL patients with COVID-19 infection were collected, aiming to identify risk factors for mortality from COVID-19. In our retrospective, multicenter, international study, we collected data from 63 MCL patients with a median age of 64 years (range, 44–84) in 9 countries with evidence of a COVID-19 infection between February 2020 and October 2021. The overall mortality rate was high (44.4%), especially in hospitalized patients (61%) and in patients with need for intensive care unit care (94%). Patients receiving rituximab had significantly poorer survival than patients not receiving rituximab (P = 0.04). Our data highlight the importance of prevention strategies and underline the need for effective vaccination in this vulnerable cohort.
